Features of the transforming growth factor β1 parameters in the blood serum among children with varying severity of bronchial asthma and varying volume of basic therapy

   Objective: the study to relationship between the concentration of transforming growth factor β1 (TGF-β1) in the blood serum of patients with bronchial asthma (BA), depending on the severity of the disease and the volume of basic therapy.

   Materials and methods. A comprehensive examination of 159 children suffering from atopic asthma was conducted, of which 79 (49.7 %) patients had mild asthma, 33 (20.75 %) had moderate asthma, and 47 (29.55 %) patients had severe asthma. The control group included 30 children of health groups I and IIa. All children included in the study had their serum concentrations of TGF-β1 determined by ELISA using Human TGF-β1 Platinum ELISA kits manufactured by Bender MedSystems GmbH, Austria (Bender MedSystems GmbH, Campus Vienna Biocenter 2, 1030 Vienna, Austria). Statistical processing of the obtained data was carried out using the Statistics 12.0 software package.

   Results. The results of the conducted studies have shown that TGF-β1 plays a significant role in the pathogenesis of asthma. And the study of changes in the concentration of this cytokine in patients depending on the volume of basic therapy makes us think about the development of new targeted therapeutic drugs to optimize pharmacotherapeutic approaches to the treatment of this disease.

   Conclusion. The results of the conducted studies showed that TGF-β1 not only plays a significant role in the pathogenesis of BA, but also affects the severity of clinical manifestations of the disease. It was found that in patients with severe asthma, TGF-β1 values were lower than in mild asthma (p = 0.009). And the study of changes in the concentration of this cytokine in patients showed the presence of increased values in patients receiving monotherapy with ICS. The results obtained are quite ambiguous and make one think about continuing research in this scientific direction.

1. Bronchial asthma: clinical guidelines. Ministry of Health of the Russian Federation. 2024.133. (In Russ.)

2. Khokha R.N., Paramonova N.S., Zavodnik L.B. The level of specific IgE and patterns of sensitization to the components of the house dust mite allergen Der p 1 and Der p 2 in children with bronchial asthma. Allergology and Immunology in Pediatrics. 2022; 1: 39-–41. (In Russ.) doi: 10.53529/2500-1175-2022-1-39-41.

3. Dzhumagaziev A.A., Savenkova N.D., Bezrukova D.A., et al. The problem of predicting the risk of developing bronchial asthma in children of early and preschool age. Astrakhan Medical Journal. 2022; 17 (1): 6-–13. (In Russ.) doi: 10.48612/agmu/2022.17.1.6.13.

4. Bokova T.A., Kartashova D.A., Troitskaya E.V., Budzinsky R.M. Clinical and epidemiological characteristics and quality of control of bronchial asthma in children living in the Moscow region. Preventive Medicine. 2022; 25 (2): 32 –36. (In Russ.) doi: 10.17116/profmed20222502132.

5. Ermakova O. A. Modern concepts of bronchial asthma among children and adolescents. Young scientist. 2019; 4: 111-–114. (In Russ.)

6. Kholbutaeva M. A., Burkhonova M. B., Babajanova Sh. R. Bronchial asthma in children : a literature review. International Journal of Scientific Research. 2025; 10 (1):, 161–167. (In Russ.)

7. Marques L., Vale N. Salbutamol in the Management of Asthma : A Review. Int. J. Mol Sci. 2022; 23 (22): 14207. doi: 10.3390/ijms232214207.

8. Berggren-Nylund R., Ryde M., Löfdahl A., et al. Effects of hypoxia on bronchial and alveolar epithelial cells linked to pathogenesis in chronic lung disorders. Front Physiol. 2023; 14: 1094245. doi: 10.3389/fphys.2023.1094245.

9. Zhuldibayeva S.Zh, Tozhialiyev I.G. Pathophysiology of Bronchial Asthma. Experimental Medicine: Today and in the Future. 2023; 1 (1),: 41–42. (In Russ.)

10. Alvarez C.A., Qian E., Glendenning L.M., et al. Acute and chronic lung inflammation drives changes in epithelial glycans. Front. Immunol. 2023; 14: 1167908. doi: 10.3389/fimmu.2023.1167908.

11. Savin I.A., Zenkova M.A., Sen’kova A.V. Bronchial Asthma, Airway Remodeling and Lung Fibrosis as Successive Steps of One Process. Int J Mol Sci. 2023; 7; 24 (22): 16042. doi: 10.3390/ijms242216042.

12. Potapova N.L., Gaymolenko I.N. Biomarkers of Airway Remodeling in Bronchial Asthma. Doctor.Ru. 2020; 19 (11): 27–31. (In Russ.) doi: 10.31550/1727-2378-2020-19-11-27-31.

13. National program “Bronchial asthma in children. Treatment strategy and prevention”. 6th ed., revised. and added. M.: Original-maket,. 2021.: 228 p. (In Russ.)

14. Paw M., Wnuk D., Madeja Z., et al. PPARδ Agonist GW501516 Suppresses the TGF-β-Induced Profibrotic Response of Human Bronchial Fibroblasts from Asthmatic Patients. Int J Mol Sci. 2023; 24 (9): 7721. doi: 10.3390/ijms24097721.

15. Hsieh A., Assadinia N., Hackett T.L. Airway remodeling heterogeneity in asthma and its relationship to disease outcomes. Front. Physiol. 2023; 14: 1113100. doi: 10.3389/fphys.2023.1113100.

16. Jaykumar A.B., Plumber S., Barry D.M., et al. WNK1 collaborates with TGF-β in endothelial cell junction turnover and angio-genesis. Proc Natl Acad Sci USA. 2022; 119 (30): e2203743119. doi: 10.1073/pnas.2203743119.

17. Du Y., Luan J., Jiang RP., et al. Myrcene exerts anti-asthmatic activity in neonatal rats via modulating the matrix remodeling. Int J Immunopathol Pharmacol. 2020; 34. doi: 10.1177/2058738420954948.

18. Sivakova L.V., Mozheiko L.V., Raspopov A.A., et al. The Role of Mediators in the Pathogenesis of Bronchial Asthma. European Journal of Natural History. 2024; 4: 24-–28. (In Russ.)

19. Uemura A., Fruttiger M., D’Amore P.A., et al. VEGFR1 Signaling in Retinal Angiogenesis and Microinflammation. Prog. Retin. Eye Res. 2021; 84: 100954. doi: 10.1016/j.preteyeres.2021.100954.

20. Katsuno Y., Derynck R. Epithelial plasticity, epithelial-mesenchymal transition, and the TGF-β family. Dev Cell. 2021; 56 (6): 726–746. doi: 10.1016/j.devcel.2021.02.028.

21. Potapova N.L., Gaymolenko I.N. Analysis of the level of transforming growth factor β1 in children with bronchial asthma. MiD. 2019; 4: 21-–25. (In Russ.)

22. Gereng E.A., Sukhodolo I.V., and Pleshko R.I. The Role of Transforming Growth Factor β1 in Structural Changes of the Bronchial Wall in Various Forms of Bronchial Inflammation. Bulletin of the Siberian Branch of the Russian Academy of Medical Sciences. 2012; 32 (5): 28–32. (In Russ.)

23. Pitsky V.I. Organ remodeling is a typical pathological process. Asthma. 2010; 11 (2): 65–74. (In Russ.)

24. Prikhodko A.G., Perelman Yu.M., Kolosov V.P. Hyperreactivity of the Airway / A.G. Prikhodko, Yu.M. Perelman, V.P. Kolosov. Dalnauka. 2011; 204. (In Russ.)

25. Postma D.S., Kerstjens H.A. Are inhaled glucocorticosteroids effective in chronic obstructive pulmonary disease? Am J Respir Crit Care Med. 1999; 160 (5 Pt 2): 66–71. doi: 10.1164/ajrccm.160.supplement_1.16. PMID: 10556173.

26. Chernysheva O.E. Markers of Airway Remodeling. Child Health. 2014; 7 (58): 80–83. (In Russ.)

27. Kraik K., Tota M., Laska J., et al. The Role of Transforming Growth Factor-β (TGF-β) in Asthma and Chronic Obstructive Pulmonary Disease (COPD). Cells. 2024; 13 (15): 1271. doi: 10.3390/cells13151271.

28. Halwani R., Al-Muhsen, S., Al-Jahdali, H., et al. Role of Transforming Growth Factor–β in Airway Remodeling in Asthma. Am. J. Respir. Cell Mol. Biol. 2012; 44: 127–133. doi: 10.1165/rcmb.2010-0027TR.

29. Doherty T., Broide D. Cytokines and Growth Factors in Airway Remodeling in Asthma. Curr. Opin. Immunol. 2007; 19: 676–680. doi: 10.1016/j.coi.2007.07.017.

30. Manuyakorn W., Kamchaisatian W., Atamasirikul K., et al. Serum TGF-B1 in Atopic Asthma. Asian Pac. J. Allergy Immunol. 2008; 26: 185–189. PMID: 19317336.

31. Todorova L., Bjermer L., Westergren-Thorsson G., et al. TGFβ-induced matrix production by bronchial fibroblasts in asthma: budesonide and formoterol effects. Respir Med. 2011; 105 (9): 1296–1307. doi: 10.1016/j.rmed.2011.03.020.